The father of Ron Goldman is closer to getting some money from O.J. Simpson, though it won't be the millions awarded by a jury decades ago when the late football and movie star was found liable for the young man's fatal stabbing.
Simpson's estate has accepted a $58 million claim from Fred Goldman, an amount that far exceeds its assets.
“It won’t be $58 million plus interest, but it will be a voluntary payment. That’s the point,” the estate's executor, Malcolm LaVergne, said Monday.
LaVergne said he's still hoping to round up $500,000 to $1 million in total assets.
Simpson died of prostate cancer in 2024 at age 76. He was found not guilty in the 1994 knife slayings of his ex-wife, Nicole Brown Simpson, and Ron Goldman, her friend, in Los Angeles.
But Simpson was taken to court again and found liable for the deaths in a separate civil case. He was ordered to pay the families $33.5 million, an award that has grown with interest.
Fred Goldman hounded Simpson for years and contended that he never willingly paid anything.
LaVergne accepted a claim of $58 million, according to a court document filed Friday in Clark County, Nevada, but not $117 million, the figure that was sought. Accepting a claim signals there won't be any time-consuming litigation over it.
Fred Goldman’s attorney, Michaelle Rafferty, said the estate has accepted the claim as valid but “it does not constitute payment.”
“We will continue to closely monitor the probate proceedings,” she said in an email.
Simpson lived in a gated golf course community in Las Vegas after serving nine years in prison for armed robbery, kidnapping and assault, all related to a confrontation with two sports memorabilia dealers in a hotel room. He typically declined to discuss his finances other than to say he lived on pensions.
FILE- This combo shows O. J. Simpson, left, and murder victims Nicole Brown Simpson, centre, and Ron Goldman, both of whom were murdered on June 12, 1994. O.J Simpson was aquitted of their murder, but will face a civil suit which has been brought by the victims' families and is scheduled to begin Tuesday, Sept. 17. (AP Photo/File)
CAMBRIDGE, England--(BUSINESS WIRE)--Mar 17, 2026--
Alchemab Therapeutics has appointed Ulrich Wendt, PhD MBA, as Chief Business Officer (CBO) to expand partnerships with biopharma for the development of novel antibody therapeutics. As a proven dealmaker and strategist, Dr Wendt brings more than a decade of experience in delivering high-value partnerships across all pipeline stages.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317585022/en/
Before joining Alchemab, he served as Global Head of Business Development Immunology at Sanofi. Prior to this, Dr Wendt drove global Business Development for Sanofi’s diabetes and primary care business units, and oversaw global search & evaluation and alliance management teams in cardiometabolic disease.
His appointment builds on Alchemab’s recent pharma licensing deals, Series A funding extension, and progression of their first asset into clinical trials.
“As CBO, Ulrich will lead Alchemab's business development and alliance management, working closely with the executive team to expand the company’s partnerships across biopharma and adjacent sectors,” said Jane Osbourn, CEO and Co-Founder of Alchemab. “He will also help guide our corporate strategy as we continue scaling our AI-enabled platform capabilities.”
With academic roots in biostructure and biophysics, Dr Wendt earned his PhD from Freiburg University, completed postdoctoral training at UC Berkeley and Genentech, and gained an MBA from IMD, Lausanne.
"Alchemab's discovery platform positions the company at the intersection of experimental and AI-enabled discovery," Dr Wendt said. "Within the last two years the company has advanced into clinical trials and delivered a stream of preclinical candidates with novel target biology. I am excited to be joining Jane and the Alchemab team at this pivotal time to help position the company for the next wave of growth."
Alchemab is a biotechnology company uncovering the immune secrets of disease-resilient individuals to discover and develop novel antibody therapeutics. Their first asset entered clinical trials in 2025 as part of a licensing deal with Lilly.
The company’s platform integrates the world's largest antibody database derived from disease-resilient individuals with a proprietary AI-powered antibody search engine designed to identify the antibodies that protect them. By pioneering this approach, Alchemab has generated a broad pipeline of treatments for hard-to-treat diseases that could not have been discovered with traditional methods.
For more information, visit alchemab.com
Dr Ulrich Wendt has been appointed Chief Business Officer at Alchemab Therapeutics
